- Home
- PCB vs NGNE Comparison
PCB vs NGNE Comparison
Compare PCB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- NGNE
- Stock Information
- Founded
- PCB 2003
- NGNE 2003
- Country
- PCB United States
- NGNE United States
- Employees
- PCB N/A
- NGNE N/A
- Industry
- PCB Major Banks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- PCB Finance
- NGNE Health Care
- Exchange
- PCB Nasdaq
- NGNE Nasdaq
- Market Cap
- PCB 289.7M
- NGNE 325.3M
- IPO Year
- PCB N/A
- NGNE N/A
- Fundamental
- Price
- PCB $22.10
- NGNE $18.48
- Analyst Decision
- PCB Hold
- NGNE Strong Buy
- Analyst Count
- PCB 2
- NGNE 7
- Target Price
- PCB $22.25
- NGNE $41.86
- AVG Volume (30 Days)
- PCB 26.5K
- NGNE 110.1K
- Earning Date
- PCB 10-23-2025
- NGNE 08-11-2025
- Dividend Yield
- PCB 3.62%
- NGNE N/A
- EPS Growth
- PCB 29.75
- NGNE N/A
- EPS
- PCB 2.14
- NGNE N/A
- Revenue
- PCB $102,259,000.00
- NGNE N/A
- Revenue This Year
- PCB $22.59
- NGNE N/A
- Revenue Next Year
- PCB $9.32
- NGNE N/A
- P/E Ratio
- PCB $10.33
- NGNE N/A
- Revenue Growth
- PCB 9.08
- NGNE N/A
- 52 Week Low
- PCB $16.00
- NGNE $6.88
- 52 Week High
- PCB $22.45
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- PCB 57.65
- NGNE 35.93
- Support Level
- PCB $21.97
- NGNE $19.59
- Resistance Level
- PCB $22.41
- NGNE $20.46
- Average True Range (ATR)
- PCB 0.38
- NGNE 1.23
- MACD
- PCB 0.05
- NGNE -0.20
- Stochastic Oscillator
- PCB 73.08
- NGNE 13.37
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.